Special Issue

Cerebrospinal Fluid Biomarkers in Dementia Disorders

Message from the Guest Editor

Alzheimer's disease and most other neurodegenerative dementia disorders are currently viewed as proteinopathies, being characterized by the aggregation of one or more protein(s) or peptides. Some of these proteins and peptides, including tau, phospho-tau. amyloid-beta, alpha-synuclein, and TDP-43, can be detected and quantified in the cerebrospinal fluid, an important means for the diagnostic workup of dementia disorders and the interpretation of underlying biochemical mechanisms. Furthermore, Alzheimer's disease (and probably other cognitive disorders) is considered as a neurobiological continuum, regardless of its clinical presentation. Thus, biomarkers may be helpful not only at the dementia stage but also across all stages of the disease(s), including the predementia symptomatic stage (mild cognitive impairment) and the preclinical stage, also contributing to early diagnosis and correct classification of subjects enrolled in clinical trials and receiving emerging, disease-modifying treatments. The upcoming Special Issue will highlight the most recent advances in the use of cerebrospinal fluid biomarkers for the diagnosis and understanding of dementing disorders.

Guest Editor

Dr. George P. Paraskevas

Second Department of Neurology, Attikon University Hospital, School of Medicine, National and Kapodistrian University of Athens, 12462 Athens, Greece

Deadline for manuscript submissions

closed (15 August 2021)



Brain Sciences

an Open Access Journal by MDPI

Impact Factor 2.8
CiteScore 5.6
Indexed in PubMed



mdpi.com/si/33176

Brain Sciences
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
brainsci@mdpi.com

mdpi.com/journal/ brainsci





Brain Sciences

an Open Access Journal by MDPI

Impact Factor 2.8 CiteScore 5.6 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Brain Sciences* (ISSN 2076-3425). *Brain Sciences* is an open access, peer-reviewed scientific journal that publishes original articles, critical reviews, research notes, and short communications on neuroscience. The scientific community and the general public can access the content free of charge as soon as it is published.

Editor-in-Chief

Prof. Dr. Stephen D. Meriney

Department of Neuroscience, University of Pittsburgh, Pittsburgh, PA 15260. USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, PSYNDEX, PsycInfo, CAPlus / SciFinder, and other databases.

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.2 days after submission; acceptance to publication is undertaken in 1.9 days (median values for papers published in this journal in the first half of 2025).

Recognition of Reviewers:

reviewers who provide timely, thorough peer-review reports receive vouchers entitling them to a discount on the APC of their next publication in any MDPI journal, in appreciation of the work done.

